Nexien BioPharma, Inc. (NXEN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Glendale, CO, United States. Der aktuelle CEO ist Richard S. Greenberg.
NXEN hat IPO-Datum 2017-11-29, gelistet an der Other OTC, eine Marktkapitalisierung von $7.08K.
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
